ASND
HEALTHCAREAscendis Pharma A/S
$235.90+10.62 (+4.71%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ASND Today?
No stock-specific AI insight has been generated for ASND yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$150.89$250.74
$235.90
Fundamentals
Market Cap$14.6B
P/E Ratio—
EPS$-4.41
Dividend Yield—
Dividend / Share—
ROE-8.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume878K
Avg Volume (10D)—
Shares Outstanding61.8M
ASND News
20 articles- Ascendis (ASND) Q1 2026 Earnings Call TranscriptMotley Fool·May 8, 2026
- European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday TradingYahoo Finance·May 7, 2026
- Ascendis Pharma A/S Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Ascendis Pharma Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 YearsYahoo Finance·May 6, 2026
- Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026Yahoo Finance·Apr 30, 2026
- Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This StockYahoo Finance·Apr 27, 2026
- European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday TradingYahoo Finance·Apr 22, 2026
- Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028Yahoo Finance·Apr 21, 2026
- European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday TradingYahoo Finance·Apr 21, 2026
- We Might See A Profit From Ascendis Pharma A/S (NASDAQ:ASND) SoonYahoo Finance·Apr 21, 2026
- Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqYahoo Finance·Apr 20, 2026
- European Equities Traded in the US as ADRs Rise in Tuesday TradingYahoo Finance·Apr 14, 2026
- Ascendis Pharma (ASND) to List Ordinary Shares Directly on NasdaqYahoo Finance·Apr 12, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Friday TradingYahoo Finance·Apr 10, 2026
- Assessing Ascendis Pharma (ASND) Valuation After New COACH Trial Data And YUVIWEL Orphan Drug ExclusivityYahoo Finance·Apr 10, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Thursday TradingYahoo Finance·Apr 9, 2026
- Ascendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire Inc.·Apr 8, 2026
- New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with AchondroplasiaYahoo Finance·Apr 8, 2026
- European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday TradingYahoo Finance·Apr 7, 2026
All 20 articles loaded
Price Data
Open$227.94
Previous Close$225.28
Day High$236.12
Day Low$224.71
52 Week High$250.74
52 Week Low$150.89
52-Week Range
$150.89$250.74
$235.90
Fundamentals
Market Cap$14.6B
P/E Ratio—
EPS$-4.41
Dividend Yield—
Dividend / Share—
ROE-8.2%
Profit Margin-0.3%
Debt / Equity—
Trading
Volume878K
Avg Volume (10D)—
Shares Outstanding61.8M
About Ascendis Pharma A/S
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—